Dirozalkib Halves Progression Risk Versus Crizotinib in First-Line ALK-Positive NSCLC
This Chinese phase III trial shows a novel ALK inhibitor beating crizotinib on progression-free survival and intracranial control, but it does not answer how it compares with the alectinib, brigatinib, or lorlatinib regimens that pharmacists see in practice.
📅 Journal publication: 2026(online Nov 10, 2026)·Last updated: Nov 12, 2026
Dirozalkib shows superior efficacy to crizotinib in ALK-positive NSCLC.
Dirozalkib offers a promising first-line treatment for ALK-positive non-small-cell lung cancer (NSCLC), especially for patients with brain metastases. Median progression-free survival (PFS) was 29.5 months for dirozalkib compared to 12.9 months for crizotinib, with fewer severe adverse events. Dirozalkib could become a preferred first-line option for ALK-positive NSCLC due to its superior efficacy and safety profile. Confirmatory real-world data are needed. Dirozalkib outperforms crizotinib in ALK-positive NSCLC, with improved PFS and tolerability.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Liu Y, Meng X, Yu Y, Chen J, Yang R, Liu L, Zhao Y, Tian R, Li D, Ning R, Li Q, Wu G, Wang L, Duan X, Guo X, Hu Y, Liu W, Liu H
Citation:Liu Y, Meng X, Yu Y, et al. Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial. Cancer communications (London, England). 2026;46:0068. doi:10.34133/cancomm.0068